Hyperhomocysteinemia, inflammation and autoimmunity

Autoimmunity Reviews

Volumn 6, Issue 7, 2007, Pages 503-509

  Lazzerini, Pietro Enea ^a   Capecchi, Pier Leopoldo ^a   Selvi, Enrico ^a   Lorenzini, Sauro ^a   Bisogno, Stefania ^a   Galeazzi, Mauro ^a   Laghi Pasini, Franco ^a  

^a UNIVERSITY OF SIENA   (Italy)

Author keywords

Autoimmunity; Homocysteine; Immune activation; Inflammation

Indexed keywords

HOMOCYSTEINE;

AUTOIMMUNE DISEASE; AUTOIMMUNITY; CARDIOVASCULAR DISEASE; ENTERITIS; HUMAN; HYPERHOMOCYSTEINEMIA; IMMUNOSTIMULATION; INFLAMMATION; PATHOGENESIS; PROTEIN BINDING; REVIEW; RHEUMATOID ARTHRITIS; RISK FACTOR;

AUTOIMMUNITY; HUMANS; HYPERHOMOCYSTEINEMIA; INFLAMMATION;

EID: 34447504842     PISSN: 15689972     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.autrev.2007.03.008     Document Type: Review

References (40)

1. Lentz S.R. Mechanisms of homocysteine-induced atherothrombosis. J Thromb Haemost 3 (2005) 1646-1654
2. de Leeuw K., Kallenberg C., and Bijl M. Accelerated atherosclerosis in patients with systemic autoimmune diseases. Ann N Y Acad Sci 1051 (2005) 362-371
3. Schroecksnadel K., Frick B., Wirleitner B., Winkler C., Schennach H., and Fuchs D. Moderate hyperhomocysteinemia and immune activation. Curr Pharm Biotechnol 5 (2004) 107-118
4. Yxfeldt A., Wallberg-Jonsson S., Hultdin J., and Rantapaa-Dahlqvist S. Homocysteine in patients with rheumatoid arthritis in relation to inflammation and B-vitamin treatment. Scand J Rheumatol 32 (2003) 205-210
5. Wallberg-Jonsson S., Cvetkovic J.T., Sundqvist K.G., Lefvert A.K., and Rantapaa-Dahlqvist S. Activation of the immune system and inflammatory activity in relation to markers of atherothrombotic disease and atherosclerosis in rheumatoid arthritis. J Rheumatol 29 (2002) 875-882
6. Schroecksnadel K., Frick B., Kaser S., Wirleitner B., Ledochowski M., Mur E., et al. Moderate hypermocysteinemia and immune activation in patients with rheumatoid arthritis. Clin Chim Acta 338 (2003) 157-164
7. Lopez-Olivo M.A., Gonzalez-Lopez L., Garcia-Gonzalez A.I., Villa-Manzano A., Cota-Sanchez A.R., Salazar-Paramo M., et al. Factors associated with hyperhomocysteinemia in Mexican patients with rheumatoid arthritis. Scand J Rheumatol 35 (2006) 112-116
8. Chiang E.P., Bagley P.J., Selhub J., Nadeau M., and Roubenoff R. Abnormal vitamin B6 status is associated with severity of symptoms in patients with rheumatoid arthritis. Am J Med 114 (2003) 283-287
9. Lazzerini P.E., Capecchi P.L., Bisogno S., Galeazzi M., Marcolongo R., and Laghi Pasini F. Reduction in plasma homocysteine levels in patients with rheumatoid arthritis given pulsed glucocorticoid treatment. Ann Rheum Dis 62 (2003) 694-695
10. Yesilova Z., Pay S., Oktenali C., Musabak U., Saglam K., Sanisoglu S.Y., et al. Hyperhomocysteinemia in patients with Behcet's disease: is it due to inflammation or therapy?. Rheumatol Int 25 (2005) 423-428
11. Chung C.P., Avalos I., Oeser A., Gebretsadik T., Shintani A., Raggi P., et al. High frequency of the metabolic syndrome in patients with systemic lupus erythematosus: association with disease characteristics and cardiovascular risk factors. Ann Rheum Dis 66 (2007) 208-214
12. Roubenoff R., Roubenoff R.A., Selhub J., Nadeau M.R., Cannon J.G., Freeman L.M., et al. Abnormal vitamin B6 status in rheumatoid cachexia. Association with spontaneous tumor necrosis factor alpha production and markers of inflammation. Arthritis Rheum 40 (1997) 718-722
13. Saibeni S., Cattaneo M., Vecchi M., Zighetti M.L., Lecchi A., Lombardi R., et al. Low vitamin B(6) plasma levels, a risk factor for thrombosis, in inflammatory bowel disease: role of inflammation and correlation with acute phase reactant. Am J Gastroenterol 98 (2003) 112-117
14. Schroecksnadel K., Frick B., Winkler C., Wirleitner B., Schennach H., and Fuchs D. Aspirin downregulates homocysteine formation in stimulated human peripheral blood mononuclear cells. Scand J Immunol 62 (2005) 155-160
15. Schroecksnadel K., Frick B., Winkler C., Wirleitner B., Weiss G., and Fuchs D. Atorvastatin suppresses homocysteine formation in stimulated human peripheral blood mononuclear cells. Clin Chem Lab Med 43 (2005) 1373-1376
16. Chiang E.P., Smith D.E., Selhub J., Dallal G., Wang Y.C., and Roubenoff R. Inflammation causes tissue-specific depletion of vitamin B6. Arthritis Res Ther 7 (2005) R1254-R1262
17. McCarty M.F. Increased homocyst(e)ine associated with smoking, chronic inflammation, and aging may reflect acute-phase induction of pyridoxal phosphatase activity. Med Hypotheses 55 (2000) 289-293
18. Hofmann M.A., Lalla E., Lu Y., Ryu Gleason M., Wolf B.M., Tanji N., et al. Hyperhomocysteinemia enhances vascular inflammation and accelerates atherosclerosis in a murine model. J Clin Invest 107 (2001) 675-683
19. Desai A., Lankford H.A., and Warren J.S. Homocysteine augments cytokine-induced chemokine expression in human vascular smooth muscle cells: implications for atherogenesis. Inflammation 25 (2001) 179-186
20. Wang G.O.K. Homocysteine stimulates the expression of monocyte chemoattractant protein-1 receptor (CCR2) in human monocytes: possible involvement of oxygen free radical. Biochem J 357 (2001) 233-240
21. Holven K.B., Aukrust P., Holm T., Ose L., and Nenseter M.S. Folic acid treatment reduces chemokine release from peripheral blood mononuclear cell in hyperhomocysteinemic subjects. Atheroscler Thromb Vasc Biol 22 (2002) 699-703
22. Su S.J., Huang L.W., Pai L.S., Liu H.W., and Chang K.L. Homocysteine at pathophysiological concentrations activates human monocyte and induces cytokine expression and inhibits macrophage migration inhibitory factor expression. Nutrition 21 (2005) 994-1002
23. Holven K.B., Aukrust P., Retterstol K., Hagve T.A., Morkrid L., Ose L., et al. Increased levels of C-reactive proteins and interleukin-6 in hyperhomocysteinemic subjects. Scand J Clin Lab Invest 66 (2006) 45-54
24. Gori A.M., Corsi A.M., Fedi S., Gazzini A., Sofi F., Bartali B., et al. A pro-inflammatory state is associated with hyperhomocysteinemia in the elderly. Am J Clin Nutr 82 (2005) 335-341
25. Tso T.K., Huang W.N., Huang H., and Chang C.K. Relationship of plasma interleukin-18 concentrations to traditional and non-traditional cardiovascular factors in patients with systemic lupus erythematosus. Rheumatology 45 (2006) 1148-1153
26. Mansoor M.A., Seljeflot I., Arnesen H., Knudsen A., Bates C.J., Mishra G., et al. Endothelial cell adhesion molecules in healthy adults during acute hyperhomocysteinemia and mild hypertriglyceridemia. Clin Biochem 37 (2004) 408-414
27. Holven K.B., Halvorsen B., Schultz H., Aukrust P., Ose L., and Nenseter M.S. Expression of matrix metalloproteinases-9 in mononuclear cells of hyperhomocystaeinemic subjects. Eur J Clin Invest 33 (2003) 555-560
28. Au-Yeung K.K.W., Woo C.W.O., Sung F.L., Yip J.C.W., Siow Y.L., and OK. Hyperhomocysteinemia activates nuclear factor-kB in endothelial cells via oxidative stress. Circ Res 94 (2004) 28-36
29. Lazzerini P.E., Selvi E., Lorenzini S., Capecchi R., Ghittoni R., Bisogno S., et al. Homocysteine enhances cytokine production in cultured synoviocytes from rheumatoid arthritis patients. Clin Exp Rheumatol 24 (2006) 387-393
30. Danese S., Sgambato A., Papa A., Scaldaferri F., Pola R., Sans M., et al. Homocysteine triggers mucosal microvascular activation in inflammatory bowel disease. Am J Gastroenterol 100 (2005) 886-895
31. Wang G., Dai J., Mao J., Zeng X., Yang X., and Wang X. Folic acid reverses hyper-responsiveness of LPS-induced chemokine secretion from monocytes in patients with hyperhomocysteinemia. Atherosclerosis 179 (2005) 395-402
32. Solini A., Santini E., and Ferrannini E. Effect of short-term folic acid supplementation on insulin sensitivity and inflammatory markers in overweight subjects. Int J Obes 30 (2006) 1197-1202
33. Dusitanond P., Eikelboom J.W., Hankey G.J., Thom J., Gilmore G., Loh K., et al. Homocysteine-lowering treatment with folic acid, cobalamin, and pyridoxine does not reduce blood markers of inflammation, endothelial dysfunction, or hypercoagulability in patients with previous transient ischemic attack or stroke: a randomised substudy of the VITATOPS trial. Stroke 36 (2005) 144-146
34. Durga J., van Tits L.J., Schouten E.G., Kok F.J., and Verhoef P. Effect of lowering of homocysteine levels on inflammatory markers: a randomized controlled trial. Arch Intern Med 165 (2005) 1388-1394
35. Jakubowski H. Biochemical basis of homocysteine toxicity in humans. Mol Cell Life Sci 61 (2004) 470-487
36. Jakubowski H. Anti-N-homocysteinylated protein autoantibodies and cardiovascular disease. Clin Chem Lab Med 43 (2005) 1011-1014
37. Undas A., Perla J., Lacinski M., Trzeciak W., Kazmierski R., and Jakubowski H. Autoantibodies against N-homocysteinylated proteins in humans: implication for atherosclerosis. Stroke 35 (2004) 1299-1304
38. Undas A., Jankowski M., Twardowska M., Padjas A., Jakubowski H., and Szczeklik A. Antibodies to N-homocysteinylated albumin as a marker for early-onset coronary artery disease in men. Thromb Haemost 93 (2005) 346-350
39. Gao X.M., Wordsworth P., McMichael A.J., Kyaw M.M., Seifert M., Rees D., et al. Homocysteine modification of HLA antigens and its immunological consequences. Eur J Immunol 26 (1996) 1443-1450
40. Chilvers M.M., Wordsworth P., Stubbs A., and Gao X.M. TCR usage by homocysteine-specific human CTL. J Immunol 160 (1998) 3737-3742